Literature DB >> 29524165

Phospholipid Magnesome-a nasal vesicular carrier for delivery of drugs to brain.

Hiba Natsheh1, Elka Touitou2.   

Abstract

The goal of this work was to investigate a new nasal carrier for enhanced drug delivery to brain, we call Phospholipid Magnesome. The system contains soft phospholipid vesicles, composed of phospholipid, water, propylene glycol, magnesium salt, and the mucoadhesive polymer, alginate. The carrier was characterized by various methods: electron microscopy, calorimetry, and dynamic light scattering. The ability of the carrier's vesicles to entrap various molecules was studied by CLSM and ultracentrifugation combined with HPLC quantification. Mucoadhesivity of the carrier was tested in vitro using porcine nasal mucosa. The delivery of rohdamine 6G, insulin, and epidermal growth factor was estimated by two methods, multiphoton microscopy and near infrared (NIR) imaging. Pharmacodynamic effects of nasal treatment with oxytocin and insulin incorporated in Phospholipid Magnesome were evaluated in animal models. Results show that the system is composed of soft multilamellar nanosized vesicles with the ability to entrap both lipophilic and hydrophilic molecules. The mucoadhesivity test results indicate a prolonged contact time of the drug with the nasal membrane as compared to control. Multiphoton microscopy and NIR imaging of brain show effective delivery of the tested molecules to brain following nasal administration in Phospholipid Magnesome relative to controls. Moreover, the results of the pharmacodynamic study measuring the antinociceptive effect of oxytocin administrated nasally to an animal model indicate the efficiency of the Phospholipid Magnesome as compared to three control systems. Further, nasal administration of insulin resulted in a strong and prolonged hypoglycemic effect for the drug incorporated in the new carrier but not for control systems. Based on the results of the histopathological test, the carrier is safe for local administration on the nasal membrane. In conclusion, the results of this study suggest that Phospholipid Magnesome nasal carrier is able to improve drug effects, probably by a combined mechanism, absorption enhancement, and prolongation of mucosal contact.

Entities:  

Keywords:  Epidermal growth factor; Insulin; Nasal delivery to brain; Oxytocin; Phospholipid Magnesome

Mesh:

Substances:

Year:  2018        PMID: 29524165     DOI: 10.1007/s13346-018-0503-y

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  24 in total

1.  Evaluation of submicron emulsion as vehicles for rapid-onset intranasal delivery and improvement in brain targeting of zolmitriptan.

Authors:  Chaoqun Yu; Pengfei Gu; Wenjun Zhang; Cuifang Cai; Haibing He; Xing Tang
Journal:  Drug Deliv       Date:  2011-08-12       Impact factor: 6.419

2.  Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterisation studies.

Authors:  S T Charlton; S S Davis; L Illum
Journal:  J Control Release       Date:  2006-12-23       Impact factor: 9.776

3.  Nasal drug delivery.

Authors:  Elka Touitou; Lisbeth Illum
Journal:  Drug Deliv Transl Res       Date:  2013-02       Impact factor: 4.617

4.  Tracking solvents in the skin through atomically resolved measurements of molecular mobility in intact stratum corneum.

Authors:  Quoc Dat Pham; Daniel Topgaard; Emma Sparr
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-27       Impact factor: 11.205

5.  Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route.

Authors:  Deepti Mittal; Shadab Md; Quamrul Hasan; Mohammad Fazil; Asgar Ali; Sanjula Baboota; Javed Ali
Journal:  Drug Deliv       Date:  2014-04-30       Impact factor: 6.419

6.  Intranasal oxytocin administration attenuates the ACTH stress response in monkeys.

Authors:  Karen J Parker; Christine L Buckmaster; Alan F Schatzberg; David M Lyons
Journal:  Psychoneuroendocrinology       Date:  2005-10       Impact factor: 4.905

7.  Correlation of two bioadhesion assays: the everted sac technique and the CAHN microbalance.

Authors:  C A Santos; J S Jacob; B A Hertzog; B D Freedman; D L Press; P Harnpicharnchai; E Mathiowitz
Journal:  J Control Release       Date:  1999-08-27       Impact factor: 9.776

8.  Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties.

Authors:  E Touitou; N Dayan; L Bergelson; B Godin; M Eliaz
Journal:  J Control Release       Date:  2000-04-03       Impact factor: 9.776

9.  Bioadhesive drug delivery systems. I. Characterisation of mucoadhesive properties of systems based on glyceryl mono-oleate and glyceryl monolinoleate.

Authors:  L S Nielsen; L Schubert; J Hansen
Journal:  Eur J Pharm Sci       Date:  1998-07       Impact factor: 4.384

10.  Oxytocin shapes the neural circuitry of trust and trust adaptation in humans.

Authors:  Thomas Baumgartner; Markus Heinrichs; Aline Vonlanthen; Urs Fischbacher; Ernst Fehr
Journal:  Neuron       Date:  2008-05-22       Impact factor: 17.173

View more
  4 in total

1.  Improved Efficiency of Pomegranate Seed Oil Administrated Nasally.

Authors:  Hiba Natsheh; Elka Touitou
Journal:  Pharmaceutics       Date:  2022-04-22       Impact factor: 6.525

Review 2.  Phospholipid Vesicles for Dermal/Transdermal and Nasal Administration of Active Molecules: The Effect of Surfactants and Alcohols on the Fluidity of Their Lipid Bilayers and Penetration Enhancement Properties.

Authors:  Hiba Natsheh; Elka Touitou
Journal:  Molecules       Date:  2020-06-27       Impact factor: 4.411

Review 3.  Polysaccharide-Based Materials Created by Physical Processes: From Preparation to Biomedical Applications.

Authors:  Paulo R Souza; Ariel C de Oliveira; Bruno H Vilsinski; Matt J Kipper; Alessandro F Martins
Journal:  Pharmaceutics       Date:  2021-04-27       Impact factor: 6.321

4.  Short Onset and Enhanced Analgesia Following Nasal Administration of Non-Controlled Drugs in Nanovesicular Systems.

Authors:  Elka Touitou; Hiba Natsheh; Shatha Boukeileh; Rania Awad
Journal:  Pharmaceutics       Date:  2021-06-28       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.